Verzenios ® ▼ (abemaciclib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

How to manage haematologic toxicities with Verzenios® ▼ (abemaciclib) in early breast cancer

Dose modification is recommended for patients who develop Grade 3 or Grade 4 haematologic toxicities. Grade 1 or Grade 2 neutropenia does not require dose modification.

UK_cFAQ_ABE026_HEMATOLOGIC_ADVERSE_EVENTS_EBC
UK_cFAQ_ABE026_HEMATOLOGIC_ADVERSE_EVENTS_EBC
en-GB

Management recommendations for haematologic toxicities with abemaciclib

Please find

    Dose modification and management recommendations for haematologic toxicities1